tbuckley/cabot-search huggingface dataset:
Confidential health services for adolescents. Council on Scientific Affairs, American Medical Association
Authors: Yank D. Coble, E. Harvey Estes, C. Alvin Head, Mitchell S. Karlan, William R. Kennedy, Patricia Joy Numann, William C. Scott, W. Douglas Skelton, Richard M. Steinhilber, Jack P. Strong, Christine C. Toevs, Henry N. Wagner, Jerod M. Loeb, Robert C. Rinaldi, Janet E. Gans
Journal: JAMA (1993)

DURING the past 20 years rates of suicide,<sup>1</sup>illicit drug use,<sup>2</sup>sexually transmissible diseases (STDs),<sup>3</sup>and births to single mothers<sup>4</sup>have increased dramatically among adolescents. The changing nature of adolescent morbidity and mortality makes it critical that they receive medical care on a timely basis, and that barriers to care are removed.<sup>5</sup>One such barrier for many adolescents is their concern about whether sensitive information shared in private with their physician will remain confidential. See also p 1404. This report reviews adolescents' need for confidential health services and support by physicians and organized medicine for confidential care. Examined are two major barriers to confidential medical care: the prerogative to provide informed consent for medical treatment and payment for health services. The report describes how physicians can balance parental involvement and adolescents' needs for privacy in health care decisions and strategies to allay parental concerns and
Allogeneic Hematopoietic Grafts After Total-Body Irradiation in Dogs With Spontaneous Tumors&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: Paul L. Weiden
 6, Rainer Storb, George E. Sale, Theodore C. Graham, E. Donnall Thomas
Journal: JNCI Journal of the National Cancer Institute (1978)

Forty outbred dogs with spontaneous malignant lymphoma-leukemia (L-L) and 20 with nonhematologic solid tumors (ST) were treated with 1,200 R total-body irradiation (TBI) and hematopoietic grafts from unrelated donors. Methotrexate and antithymocyte serum were administered post grafting to suppress graft-versus-host disease (GVHD). Most dogs died in less than 14 days of complications related to TBI-induced myelosuppression. Sixteen dogs with L-L, however, survived more than 14 days. Fifteen of these dogs died between 16 and 65 days (median, 23 days), 13 with GVHD and 2 with graft rejection. Fourteen of the 15 were free of L-L at autopsy and 1 had a single lymphomatous nodule of the spleen. One of the 16 dogs with L-L developed recurrent leukemia in host cells 1 year after initial therapy. This dog was given another 1,200 R TBI and a graft from a different unrelated donor but died 53 days later of GVHD without evidence of tumor. Survival of more than 14 days among dogs with L-L could not be related to clinical status before grafting, overt leukemia, therapy prior to TBI, or to the number of hematopoietic cells transfused. Five dogs with ST survived more than 14 days (range, 21–78 days; median, 26 days). All died with persistent tumor; 4 also had GVHD. In a previous study, we had shown that recurrent or persistent tumor was the chief cause of death in dogs with L-L and ST that survived more than 14 days following TBI and autologous marrow grafting. The current study thus demonstrated that dogs with L-L, but not dogs with ST, living more than 14 days following 1,200 R TBI were more likely to be free of tumor if they received an allogeneic marrow graft than if they received an autologous marrow graft (P<0.005). Several factors may have contributed to this observed difference.
Benign multiple sclerosis.
Journal: BMJ (1977)

1977 lesions than the patients in earlier reports of either coronary or femoral atheroma.Thus Knight et al7 found regression of coronary lesions in only three out of 22 patients with hyper- cholesterolaemia after surgical partial ileal bypass had pro- duced an average 4000 lowering of serum cholesterol concen- trations.The message seems abundantly clear.
Prevalence and Health Consequences of Stalking—Louisiana, 1998-1999
Journal: JAMA (2000)

CDC HAS CONTRACTED WITH AVENTIS-Pasteur, Inc. (Av-P) for the production of 9 million doses of influenza vaccine for the 2000-01 season.This additional production ensures that approximately the same quantity of influenza vaccine is available for the 2000-01 season as the previous year. 1,2 The 9 million doses are not intended to substitute for vaccine that is already ordered and expected to be delivered.For the 1999-2000 influenza season, approximately 77 million doses of influenza vaccine were distributed in the United States, of which 3 million doses were returned to the manufacturers.For the 2000-2001 influenza season, distribution of approximately 75 million doses is anticipated, including the 9 million doses contracted by CDC.Av-P will give first priority to orders from providers who plan to vaccinate primarily high-risk persons.Applications for vaccine orders from health-care providers and programs should be sent directly to Av-P beginning November 3, 2000.Wholesale distributors can apply to purchase vaccine starting December 4, 2000, if doses remain available.Once an application has been received by Av-P, notification regarding order acceptance will be provided to the applicant before mid-December.Delivery of vaccine is anticipated to begin December 12, 2000, and end by early January 2001.Additional information about the application process and vaccine availability is available through Av-P, tele-phone (800) 720-8972, or World-Wide Web, http://www.vaccineshoppe.com(click on Fluzone (Registered) Application Form link).Completed application forms can be faxed to (888) 889-7129.Orders for this vaccine will not be taken by telephone.CDC's National Immunization Program (NIP) has developed an "Influenza Vaccine Availability" website that will provide information about the availability of influenza vaccine from manufacturers and wholesale distributors and will list state health departments that may have information about vaccine availability among local providers.This website will be updated weekly.The website can be accessed at http://www.cdc .gov/nip/flu-vac-supply.
"FURTHER NEW ZOOPARASITES OF MAN"
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Patient Satisfaction Among Elderly Enrollees and Disenrollees in Medicare Health Maintenance Organizations
Authors: Louis F. Rossiter
Journal: JAMA (1989)

More than 1 million Medicare beneficiaries have enrolled in health maintenance organizations (HMOs) and competitive medical plans under a new program in which beneficiaries can freely enroll in a risk-based HMO in their area or remain in the fee-for-service sector under Medicare. Based on a randomly selected nationwide sample of beneficiaries, we analyzed differences in patient satisfaction between 2091 beneficiaries who were continuously enrolled in an HMO plan for 1 year and 1000 beneficiaries in the fee-for-service sector. We also studied the reasons for disenrollment. No significant difference in overall satisfaction was found between HMO enrollees and fee-for-service beneficiaries. However, HMO enrollees expressed less satisfaction compared with fee-for-service beneficiaries regarding the professional competence of their health care providers and the willingness of the HMO staff to discuss problems. On the other hand, HMO enrollees were more satisfied than fee-for-service beneficiaries with waiting times and claims processing. Approximately half of the disenrollment from an HMO within 1 year was attributed to misunderstanding the terms of enrollment. (<i>JAMA</i>. 1989;262:57-63)
Abnormal Patency of the Eustachian Tube
Authors: George W. Allen
Journal: JAMA (1967)

ALL OF THE ESSENTIAL features of the condition of abnormal patency of the eustachian tube were described by Jago,<sup>1</sup>who himself suffered from it, in 1867. It is characterized by an unpleasant feeling of tension upon the ear drum, an abnormal loudness of the voice and respiratory sounds in the affected ear termed "autophony," absence of deafness, and a normal appearance of the tympanic membrane. Jago discovered that the tube could be made to close temporarily by a sudden inspiratory effort with nose and mouth held closed. Symptoms also disappeared after a period during which he gained weight. After 14 years of practice, he had discovered only one other case. For many years this was considered to be a very rare entity, being found usually in association with rapid weight loss. It seems more likely that it has been overlooked or misdiagnosed. Although there are brief references to pregnancy
Immunological Changes and Hyposensitization Therapy
Authors: Vincent J. Fontana
Journal: JAMA (1968)

<h3>To the Editor:—</h3> I read with interest the very fine objective approach to hyposensitization therapy by Pruzansky and Patterson, "Immunologic Changes During Hyposensitization Therapy," (<b>203</b>:607, 1968). This work is particularly important in view of the difficulties of assessing the effectiveness of hyposensitization therapy dependent on subjective evaluation. The search for more objective means of evaluating hyposensitization therapy should be considered one of the major objectives in allergy research. The triple investigational approach, described by the authors, in which antibody production, cell reactivity, and clinical measurements are used for assessment of immunization procedures in allergic disease appear promising; its validity, of course, will be dependent on continued studies in this area. It is hoped that investigators in this field will recognize the heterogeneity of patients. This factor is probably, in part, responsible for the conflicting reports on the value of immunization therapy.<sup>1,2</sup> The patients evaluated by these objective laboratory
Is it time to stop searching for MRSA?
Authors: R Philp, R McCann, P Rowland, J K Torrens, R D Jefferson, J Harrison, G. Cattermole, R K Peel, I Stolarek, A T Elder, P. Wilson, L J Dunn, K. Loudon, J. P Burnie, R P D Cooke, R S Umasankar, S V Goddard, D A B Dance, R Cunningham, P N Gaunt, V J Stewart, J Swales
Journal: BMJ (1997)
The Socialization of Medicine.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Inhibition of Spontaneous Development of Hyperplastic Alveolar Nodules and Mammary Tumors in C3H Mice Fed Phenylalanine-Deficient Diets&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Journal: JNCI Journal of the National Cancer Institute (1971)

Journal Article Inhibition of Spontaneous Development of Hyperplastic Alveolar Nodules and Mammary Tumors in C3H Mice Fed Phenylalanine-Deficient Diets Get access Y. H. Hui, Y. H. Hui Cancer Research Genetics Laboratory and the Department of Nutritional Sciences, University of California, Berkeley, California 94720 Search for other works by this author on: Oxford Academic PubMed Google Scholar K. B. DeOme, K. B. DeOme Cancer Research Genetics Laboratory and the Department of Nutritional Sciences, University of California, Berkeley, California 94720 Search for other works by this author on: Oxford Academic PubMed Google Scholar G. M. Briggs G. M. Briggs Cancer Research Genetics Laboratory and the Department of Nutritional Sciences, University of California, Berkeley, California 94720 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 47, Issue 3, September 1971, Pages 687–695, https://doi.org/10.1093/jnci/47.3.687 Published: 01 September 1971 Article history Received: 21 April 1971 Accepted: 21 May 1971 Published: 01 September 1971
Cancer of the gastrointestinal tract. Surgical treatment of gastric adenocarcinoma
Authors: R. Menguy
Journal: JAMA (1974)

BECAUSE glandular carcinomas of the stomach are not very sensitive to roentgen therapy, and respond poorly, if at all, to the chemotherapeutic agents currently available, the only possible curative solution to gastric carcinoma is surgical excision of the lesion. The operation should be performed prior to the development of metastases beyond the confines of the stomach and adjacent lymphatic pathways. The history of surgery of gastric cancer began in 1881 when Billroth<sup>9</sup>performed the first partial gastrectomy for cancer. In 1897, Schlatter<sup>10</sup>performed the first total gastrectomy for cancer. During the first half of this century, surgical operations for gastric cancer became more and more extensive, and surgical techniques and knowledge of preoperative and postoperative care reached greater degrees of sophistication. By the 1940s, a total gastrectomy had become the operation of choice for gastric cancer in many clinics throughout the world. During the early 1950s, in some
Trivalent Combined Measles-Mumps-Rubella Vaccine
Authors: Joseph Stokes
Journal: JAMA (1971)

Four lots of combined trivalent Moraten measles, Jeryl Lynn mumps, and HPV-77 duck rubella vaccine were administered to a total of 715 children, 7 months to 7 years of age, who were initially without antibody against any of the three viruses. Overall, 96% of the children developed measles hemagglutination-inhibiting, 95% developed mumps neutralizing, and 94% developed rubella hemagglutination-inhibiting antibodies. The most important clinical reaction to the trivalent vaccine was mild fever in a portion of the children, such as is expected following administration of Moraten measles vaccine alone. Joint involvement was notably absent during the six-to-nine week follow-up. The combined measles-mumps-rubella vaccine provides a simple means for immunizing against all three of these diseases without impairment of antibody response and without significant increase in clinical reaction.
NIH research findings: Recent studies show workers exposed to asbestos years ago are at a greater risk for some diseases
Journal: JAMA (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pharmacology and therapeutics
Authors: A Taha, R Sturrock, R Russell
Journal: Gut (1992)

The conflicting reports on Gold and H pylori could be related to the use of serological tests of unproven value in NSAID patients, and to the lack of the appropriate control groups.More importantly, the endoscopic consequences of the possible effect of Gold on H pylori have not been investigated.We studied the prevalence of H pylori and peptic ulcers in patients with rheumatoid arthritis being treated with NSAID only and NSAID plus intramuscular Gold.Another control group was included, which consisted of patients receiving NSAID plus Sulpha- salazine.Both Gold and Sulphasalazine are known to have similar anti-inflammatory activity.NSAID, Gold and Sulphasalazine had to be taken for at least six months.
Diagnosis and Treatment of Human Fascioliasis
Authors: John W. Hadden
Journal: JAMA (1967)

Human<i>Fasciola hepatica</i>infection is a rare entity involving infestation of the liver and biliary tree with adult flukes, which can result in hepatitis, cirrhosis, and biliary tract inflammation, obstruction, and lithiasis. The patient had the typical diagnostic tetrad of fever, eosinophilic leukocytosis, tender hepatomegaly, and fluke ova in the stools. Treatment consists of emetine hydrochloride administration for hepatic involvement and common duct exploration for removal of flukes, with cholecystectomy for associated cholelithiasis. The combination of medical and surgical therapy can be expected to produce an arrest of this infection.
Failure of Corticosteroid to Potentiate Sympathomimetic Pressor Response During Shock
Authors: Herbert Shubin
Journal: JAMA (1966)

Corticosteroids administered in an emergency neither increase arterial pressure nor enhance the pressor response to levarterenol (norepinephrine) in normotensive human subjects with normal adrenal function.<sup>1,2</sup>In rats, dogs, and humans<sup>3</sup>who have adrenocortical insufficiency, however, corticosteroid hormones clearly increase the pressor response to sympathomimetic amines. These facts have led to the presumption of adrenocortical insufficiency in cases of circulatory shock in which responsiveness to vasopressor amines is diminished. Yet there is neither experimental nor clinical confirmation of adrenocortical insufficiency in shock following hemorrhage or shock complicating infection; to the contrary, the output of adrenocortical hormone is tripled. Nevertheless, the clinical impression persists that during shock corticosteroids enhance the pressor response to catecholamines. <h3>Clinical Material.—</h3> Nine patients, four men and five women, ranging from 41 to 76 years of age, hospitalized in the Los Angeles County General Hospital, were the subjects of investigation. Clinical features of shock were documented
CHICAGO MEDICAL SOCIETY.
Journal: JAMA (1885)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Inhibitory Effect of Fumaric Acid on 3-Methyl-4′-(dimethylamino)azobenzene-Induced Hepatocarcinogenesis in Rats
Authors: Keiko Kuroda, Kiyoshi Terao, Mitsutaro Akao
Journal: JNCI Journal of the National Cancer Institute (1983)

umaric acid (FA) was examined for its effect on hepatocarcinogenesis in rats fed 3-methyl-4′-(dimethylamino)azobenzene (3-Me-DAB). Male DONRYU rats were given approximately 0.5 g 3-MeDAB by being fed a diet containing 0.06% 3-Me-DAB for 50 days; they were then given a diet containing 1% FA and drinking water containing 0.025% FA for 51 weeks. The administration of FA effectively suppressed the development of hepatocellular carcinoma, hyperplastic nodules, and hyperplastic areas in the livers of rats fed 3-Me-DAB.
Aerosols and Aerosol Propellants in Asthma
Authors: Minas Joannides
Journal: JAMA (1971)

<h3>To the Editor.—</h3> In my practice of diseases of the chest, I have at least 1,000 patients who use and rely on a pressured aerosol device containing isoproterenol. Depending on the extent of their respiratory embarrassment, they use this device from 1 to 20 times a day. All these patients suffer from asthma, bronchitis, or emphysema and have been shown to have a bronchospastic component to their disease by objective pulmonary function testing in my laboratory. In addition, I have given at least 30,000 consecutive intermittent positive pressure breathing (IPPB) treatments utilizing a pressure aerosol device containing isoproterenol, in line with the stream, without any major or minor side effect or complication. My patients, who own their own IPPB machines at home, have probably given themselves a similar number of treatments utilizing the aerosol device with no complications.
Roentgenographic Diagnosis of Congenital Syphilis in the Newborn
Authors: David R. Coblentz
Journal: JAMA (1970)

An increased incidence of congenital syphilis at the Los Angeles County-University of Southern California Medical Center seems to reflect the findings of general public health surveys. The role of the radiologist in the discovery of congenital syphilis is emphasized. In our experience, multiple long-bone changes in the first weeks of life are most frequently due to congenital syphilis. A differential diagnosis may be considered.